cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.5127334.v1
title: Supplementary Material for: Apoptosis-Related Gene Expression Profile in Chronic Myeloid Leukemia Patients after Imatinib Mesylate and Dasatinib Therapy

description: <b><i>Background/Aims:</i></b> We investigated the effects of tyrosine kinase inhibitors (TKIs) on the expression of apoptosis-related genes (BCL-2 and death receptor family members) in chronic myeloid leukemia (CML) patients. <b><i>Methods:</i></b> Peripheral blood mononuclear cells from 32 healthy subjects and 26 CML patients were evaluated before and after treatment with imatinib mesylate (IM) and dasatinib (DAS) by quantitative PCR. <b><i>Results:</i></b> Anti-apoptotic genes <i>(c-FLIP </i>and<i> MCL-1)</i> were overexpressed and the pro-apoptotic <i>BIK </i>was reduced in CML patients. Expression of <i>BMF, A1, c-FLIP, MCL-1, CIAP-2 </i>and <i>CIAP-1 </i>was modulated by DAS. In IM-resistant patients, expression of <i>A1, c-FLIP, CIAP-1</i> and <i>MCL-1 </i>was upregulated, and <i>BCL-2</i>,<i> CIAP-2</i>,<i> BAK, BAX, BIK </i>and <i>FASL </i>expression was downregulated. <b><i>Conclusion:</i></b> Taken together, our results point out that, in CML, DAS interferes with the apoptotic machinery regulation. In addition, the data suggest that apoptosis-related gene expression profiles are associated with primary resistance to IM.
DOI: 10.6084/m9.figshare.5127322
title: Supplementary Material for: Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer

description: The immune system represents a significant barrier to successful gene therapy with adeno-associated viral (AAV) vectors. In particular, adaptive immune responses to the viral capsid or the transgene product are of concern. The sensing of AAV by toll-like receptors (TLRs) TLR2 and TLR9 has been suggested to play a role in innate immunity to the virus and may also shape subsequent adaptive immune responses. Here, we investigated the functions of TLR2, TLR9 and the downstream signaling adaptor MyD88 in antibody and CD8+ T-cell responses. Antibody formation against the transgene product occurred largely independently of TLR signaling following gene transfer with AAV1 or AAV2 vectors, whereas loss of signaling through the TLR9-MyD88 pathway substantially reduced CD8+ T-cell responses. In contrast, MyD88 (but neither of the TLRs) regulated antibody responses to capsid. B cell-intrinsic MyD88 was required for the formation of anti-capsid IgG2c independently of vector serotype or route of administration. However, MyD88<sup>-/-</sup> mice instead produced anti-capsid IgG1 that emerged with delayed kinetics but nonetheless completely prevented in vivo readministration. We conclude that there are distinct roles for TLR9 and MyD88 in promoting adaptive immune responses to AAV-mediated gene transfer and that there are redundant MyD88-dependent and MyD88-independent mechanisms that stimulate neutralizing antibody formation against AAV.
DOI: 10.6084/m9.figshare.5127325
title: Supplementary Material for: Bronchogenic Stress Cardiomyopathy: A Case Series

description: Despite a growing awareness of stress (takotsubo) cardiomyopathy, the diversity in precipitants beyond emotional distress remains under-appreciated. Emerging data implicate a differential influence of precipitant type on the variable presentations of stress cardiomyopathy. We outline 5 cases of stress cardiomyopathy where the precipitant was an acute exacerbation of chronic obstructive pulmonary disease treated with high-dose bronchodilator therapy. In this setting, an atypical and insidious presentation of the stress cardiomyopathy was consistently observed that was difficult to distinguish from the acute airway exacerbation itself, with an absence of chest pain in particular. Scrutiny of published single-case reports reveals a similar atypical presentation; this supports the existence of a novel bronchogenic subgroup of stress cardiomyopathy. A key role of repeat ECG evaluation in distinguishing protracted but uncomplicated bronchospasm from bronchogenic stress cardiomyopathy is highlighted. Further data are now required to examine whether high-dose β-agonist therapy is implicated in this association.
DOI: 10.6084/m9.figshare.5127328
title: Supplementary Material for: Multifaceted Intervention Including Motivational Interviewing to Support Medication Adherence after Stroke/Transient Ischemic Attack: A Randomized Trial

description: <b><i>Background and Purpose:</i></b> Adherence to medication is often suboptimal after stroke and transient ischemic attack (TIA), which increases the risk of recurrent stroke and death. Complex interventions and motivational interviewing (MI) have been proven effective in other areas of medicine. The objective of this study was to investigate the effectiveness of a multifaceted intervention including MI in improving medication adherence for secondary stroke prevention. <b><i>Methods:</i></b> In this randomized controlled trial, TIA and stroke patients receiving a pharmacist intervention in a hospital setting were compared with patients receiving usual care. The intervention consisted of a focused medication review, an MI-approached consultation and 3 follow-up telephone calls and lasted for 6 months. The primary outcome was a composite medication possession ratio (MPR) for antiplatelets, anticoagulants and statins in the year after hospitalization, assessed by analyzing pharmacy records and reported as both a continuous rate and a binary outcome. Secondary outcomes included composite MPRs at 3, 6 and 9 months as well as adherence and persistence to specific thrombopreventive medications at 12 months. Clinical outcomes included a combined end point of cardiovascular death, stroke or acute myocardial infarction. Patient satisfaction with the service was assessed for the intervention patients. <b><i>Results:</i></b> The analyses included 102 intervention patients and 101 controls. At 12 months, the median MPRs (IQR) were 0.95 (0.77-1) in the intervention group and 0.91 (0.83-0.99) in the control group, and 28 and 21% of the patients, respectively, were nonadherent (MPR &lt;0.80; risk difference: 7%; 95% CI: -5 to 19%). In both groups, the median MPR decreased over time. From 3 to 12 months, the MPR fell by 5% (p &lt; 0.05) in the intervention group and by 9% (p &lt; 0.05) in the control group, but between the groups, comparisons showed no statistically significant difference. No significant differences were found for adherence and persistence to specific thrombopreventive agents or for the clinical outcome. The intervention patients were satisfied with the service; about half of them reported increased knowledge about medication, and one third reported increased confidence with medication use. Pharmacists identified drug-related problems in one third of the patients. <b><i>Conclusions:</i></b> A multifaceted pharmacist intervention including MI did not improve adherence or persistence to secondary stroke prevention therapy and had no impact on clinical outcomes. However, due to the high adherence rates, only little room for improvement existed. Future studies should focus on patients at high risk of nonadherence and include outcomes more sensitive to the impact of behavioral interventions.
DOI: 10.6084/m9.figshare.5127343.v1
title: Supplementary Material for: Treatment Efficacy Differences of Sorafenib for Advanced Hepatocellular Carcinoma: A Meta-Analysis of Randomized Clinical Trials

description: <b><i>Objectives:</i></b> Hepatocellular carcinoma (HCC) is a heterogeneous disease. We explored whether any specific subgroups of patients may gain more survival benefits from sorafenib as the first-line therapy for advanced HCC. <b><i>Methods:</i></b> PubMed and the Cochrane library were searched for phase III clinical trials that compared sorafenib with other treatments as first-line therapy for advanced HCC. We retrieved data from the published articles and then calculated synthesized hazard ratios (HRs) of overall mortality for patients of different subgroups, using patients who received other treatments as the reference. <b><i>Results:</i></b> Four phase III clinical trials comparing sorafenib with other treatments were included in this study. The HRs were not significantly different between patients from various geographic regions (p = 0.183), patients with different Eastern Cooperative Oncology Group performance statuses (p = 0.699), or patients with different tumor involvement (p = 0.221). By contrast, the synthesized HR for hepatitis C virus (HCV)+ patients was 0.65 [95% confidence interval (CI) 0.53-0.80], which was significantly lower than that for HCV- patients (0.87, 95% CI 0.79-0.96, p = 0.013). <b><i>Conclusions:</i></b> As the first-line therapy for advanced HCC, sorafenib might provide more survival benefits to HCV+ patients than to HCV- patients.
DOI: 10.6084/m9.figshare.5127316
title: Supplementary Material for: Acrobatic Courtship Display Coevolves with Brain Size in Manakins (Pipridae)

description: Acrobatic display behaviour is sexually selected in manakins (Pipridae) and can place high demands on many neural systems. Manakin displays vary across species in terms of behavioural complexity, differing in number of unique motor elements, production of mechanical sounds, cooperation between displaying males, and construction of the display site. Historically, research emphasis has been placed on neurological specializations for vocal aspects of courtship, and less is known about the control of physical, non-vocal displays. By examining brain evolution in relation to extreme acrobatic feats such as manakin displays, we can vastly expand our knowledge of how sexual selection acts on motor behaviour. We tested the hypothesis that sexual selection for complex motor displays has selected for larger brains across the Pipridae. We found that display complexity positively predicts relative brain weight (adjusted for body size) after controlling for phylogeny in 12 manakin species and a closely related flycatcher. This evidence suggests that brain size has evolved in response to sexual selection to facilitate aspects of display such as motor, sensorimotor, perceptual, and cognitive abilities. We show, for the first time, that sexual selection for acrobatic motor behaviour can drive brain size evolution in avian species and, in particular, a family of suboscine birds.
DOI: 10.6084/m9.figshare.5127319
title: Supplementary Material for: Clinical Implications from a Single-Center Study of Colorectal Adenocarcinoma in Transplant Recipients

description: <b><i>Background:</i></b> With the increasing burden of organ transplant recipients and improvements in allograft outcome, the incidence of neoplasms rising from these patients is an important issue. <b><i>Objective:</i></b> In this study, we investigated transplant recipients with colorectal cancer to determine its incidence, clinicopathological characteristics, and prognosis. <b><i>Methods:</i></b> The database of Severance Hospital was queried for all cases of colorectal adenocarcinoma among transplant recipients from August 2005 to January 2013. <b><i>Results:</i></b> A total of 29 patients were diagnosed with colorectal adenocarcinoma after transplantation, and the median age at diagnosis was 58.6 years. As for primary tumor stage, 17 (58.6%) patients had stage ≥3, and distant metastasis was found in 10 (34.4%) patients. The mean time from transplantation to tumor detection was 13.7 years. The median disease-free survival was 11.0 months and the median overall survival (OS) was 18.1 months. In multivariate analysis of prognostic factors for OS, surgical resection was a positive prognostic factor (HR 1.357, p = 0.010) and the presence of distant metastasis at diagnosis was a negative prognostic factor (HR 1.047, p = 0.006). <b><i>Conclusion:</i></b> The behavior of colorectal cancer in posttransplant patients is more aggressive and refractory to treatment. A separate guideline for the colorectal screening program for the posttransplant patients needs to be established. © 2014 S. Karger AG, Basel
DOI: 10.6084/m9.figshare.5127307
title: Supplementary Material for: Long-Term Follow-Up of Chronic Hepatitis C Patients Treated with Interferon-Alpha: Risk of Cirrhosis and Hepatocellular Carcinoma in a Single Center over 10 Years

description: <b><i>Objectives:</i></b> Interferon (IFN)-based therapy for chronic hepatitis C (CHC) is cost-effective and is associated with reduced risk of disease progression. We aimed to assess the incidence of cirrhosis and hepatocellular carcinoma (HCC) and to identify risk factors associated with disease progression. <b><i>Methods:</i></b> We retrospectively reviewed 280 CHC patients who were registered at our hospital between 2001 and 2010. <b><i>Results:</i></b> About 80% of patients received antiviral treatment. The 10-year cumulative incidence of cirrhosis was significantly lower among patients who received antiviral therapy than among those who did not (8.3 vs. 44.0%; p = 0.001). Among them, patients with sustained virological response (SVR) had a significantly lower incidence of cirrhosis than those without SVR (0.6 vs. 33.9%; p &lt; 0.001). Cox proportional hazards regression showed that SVR was the significant independent factor for reducing the risk of cirrhosis (hazard ratio, HR = 0.03; p = 0.034). The 10-year cumulative incidence of HCC was higher among patients who did not receive antiviral therapy than among those who did (43.9 vs. 6.1%; p &lt; 0.001). Multivariate analysis showed that underlying cirrhosis was the only independent risk factor associated with HCC development (HR = 7.70; p = 0.010). <b><i>Conclusions:</i></b> SVR secondary to IFN-based therapy could reduce cirrhosis development in CHC patients. Underlying cirrhosis was the strongest predictor of HCC development.
DOI: 10.6084/m9.figshare.5127310
title: Supplementary Material for: Biochemical Characterization and Antioxidant and Antiproliferative Activities of Different <b><i>Ganoderma </i></b>Collections

description: The aim of this study was to conduct a molecular and biochemical characterization and to compare the antioxidant and antiproliferative activities of four <i>Ganoderma</i> isolates belonging to <i>Ganoderma lucidum</i> (Gl-4, Gl-5) and <i>Ganoderma resinaceum</i> (F-1, F-2) species. The molecular identification was performed by ITS and IGS sequence analyses and the biochemical characterization by enzymatic and proteomic approaches. The antioxidant activity of the ethanolic extracts was compared by three different methods and their flavonoid contents were also analyzed by high-performance liquid chromatography. The antiproliferative effect on U937 cells was determined by MTT assay. The studied mycelia differ both in the enzymatic activities and protein content. The highest content in total phenol and the highest antioxidant activity for DPPH free radical scavenging and chelating activity on Fe<sup>2+</sup> were observed with the Gl-4 isolate of <i>G. lucidum</i>. The presence of quercetin, rutin, myricetin, and morin as major flavonoids with effective antioxidant activity was detected. The ethanolic extracts from mycelia of <i>G. lucidum</i> isolates possess a substantial antiproliferative activity against U937 cells in contrast to <i>G. resinaceum</i> in which the antiproliferative effects were insignificant. This study provides a comparison between <i>G. lucidum</i> and <i>G. resinaceum</i> mycelial strains, and shows that <i>G. resinaceum</i> could be utilized to obtain several bioactive compounds.
DOI: 10.6084/m9.figshare.5127313
title: Supplementary Material for: Ultrasonographic versus Fluoroscopic Access for Percutaneous Nephrolithotomy: A Meta-Analysis

description: <b><i>Objective:</i></b> To assess the safety and efficacy of ultrasonographic vs. fluoroscopic access for percutaneous nephrolithotomy (PCNL). <b><i>Methods:</i></b> Medline (PubMed), Embase, Ovid, Cochrane, and the Chinese Biomedical Literature databases were searched to identify clinically controlled trials (CCTs) and randomized controlled trials (RCTs) that compared ultrasonographic access with fluoroscopic access for PCNL. RevMan 5.1 software and Stat Manager V4.1 software were used for the meta-analysis. <b><i>Results:</i></b> Five RCTs and nine CCTs were included in our study, which contained a total of 3,019 patients. Of these, 1,574 (52%) had undergone ultrasonographic access, and 1,445 (48%) had undergone fluoroscopic access. The pooled results revealed that the ultrasonographic access patients had shorter duration of access (min) by 2.56 min (weighted mean difference (WMD) = −2.56, 95% confidence interval (CI): −4.40 to −0.72, p = 0.006). There was a higher stone-free rate in the ultrasonographic access group (odds ratio (OR) = 1.26, 95% CI: 1.02-1.55, p = 0.03), as well as a lower rate of operative complications (OR = 0.72, 95% CI: 0.56-0.93, p = 0.01), reduced intraoperative blood loss (ml) (WMD = −14.55 ml, 95% CI: −27.65 to −1.46, p = 0.03), and a lower rate of blood transfusion requirement (OR = 0.39, 95% CI: 0.24-0.63, p = 0.0001). Sensitivity and subgroup analyses were also performed. <b><i>Conclusion:</i></b> Except for no radiation exposure, our meta-analysis revealed that ultrasonographic access had many advantages, such as a shorter access time, reduced intraoperative blood loss, a lower rate of operative complications, a lower rate of blood transfusion, and a higher stone-free rate. Because of these significant advantages, we recommend the use of ultrasonographic access for PCNL.
DOI: 10.6084/m9.figshare.5127319.v1
title: Supplementary Material for: Clinical Implications from a Single-Center Study of Colorectal Adenocarcinoma in Transplant Recipients

description: <b><i>Background:</i></b> With the increasing burden of organ transplant recipients and improvements in allograft outcome, the incidence of neoplasms rising from these patients is an important issue. <b><i>Objective:</i></b> In this study, we investigated transplant recipients with colorectal cancer to determine its incidence, clinicopathological characteristics, and prognosis. <b><i>Methods:</i></b> The database of Severance Hospital was queried for all cases of colorectal adenocarcinoma among transplant recipients from August 2005 to January 2013. <b><i>Results:</i></b> A total of 29 patients were diagnosed with colorectal adenocarcinoma after transplantation, and the median age at diagnosis was 58.6 years. As for primary tumor stage, 17 (58.6%) patients had stage ≥3, and distant metastasis was found in 10 (34.4%) patients. The mean time from transplantation to tumor detection was 13.7 years. The median disease-free survival was 11.0 months and the median overall survival (OS) was 18.1 months. In multivariate analysis of prognostic factors for OS, surgical resection was a positive prognostic factor (HR 1.357, p = 0.010) and the presence of distant metastasis at diagnosis was a negative prognostic factor (HR 1.047, p = 0.006). <b><i>Conclusion:</i></b> The behavior of colorectal cancer in posttransplant patients is more aggressive and refractory to treatment. A separate guideline for the colorectal screening program for the posttransplant patients needs to be established. © 2014 S. Karger AG, Basel
DOI: 10.6084/m9.figshare.5127307.v1
title: Supplementary Material for: Long-Term Follow-Up of Chronic Hepatitis C Patients Treated with Interferon-Alpha: Risk of Cirrhosis and Hepatocellular Carcinoma in a Single Center over 10 Years

description: <b><i>Objectives:</i></b> Interferon (IFN)-based therapy for chronic hepatitis C (CHC) is cost-effective and is associated with reduced risk of disease progression. We aimed to assess the incidence of cirrhosis and hepatocellular carcinoma (HCC) and to identify risk factors associated with disease progression. <b><i>Methods:</i></b> We retrospectively reviewed 280 CHC patients who were registered at our hospital between 2001 and 2010. <b><i>Results:</i></b> About 80% of patients received antiviral treatment. The 10-year cumulative incidence of cirrhosis was significantly lower among patients who received antiviral therapy than among those who did not (8.3 vs. 44.0%; p = 0.001). Among them, patients with sustained virological response (SVR) had a significantly lower incidence of cirrhosis than those without SVR (0.6 vs. 33.9%; p &lt; 0.001). Cox proportional hazards regression showed that SVR was the significant independent factor for reducing the risk of cirrhosis (hazard ratio, HR = 0.03; p = 0.034). The 10-year cumulative incidence of HCC was higher among patients who did not receive antiviral therapy than among those who did (43.9 vs. 6.1%; p &lt; 0.001). Multivariate analysis showed that underlying cirrhosis was the only independent risk factor associated with HCC development (HR = 7.70; p = 0.010). <b><i>Conclusions:</i></b> SVR secondary to IFN-based therapy could reduce cirrhosis development in CHC patients. Underlying cirrhosis was the strongest predictor of HCC development.
DOI: 10.6084/m9.figshare.5127310.v1
title: Supplementary Material for: Biochemical Characterization and Antioxidant and Antiproliferative Activities of Different <b><i>Ganoderma </i></b>Collections

description: The aim of this study was to conduct a molecular and biochemical characterization and to compare the antioxidant and antiproliferative activities of four <i>Ganoderma</i> isolates belonging to <i>Ganoderma lucidum</i> (Gl-4, Gl-5) and <i>Ganoderma resinaceum</i> (F-1, F-2) species. The molecular identification was performed by ITS and IGS sequence analyses and the biochemical characterization by enzymatic and proteomic approaches. The antioxidant activity of the ethanolic extracts was compared by three different methods and their flavonoid contents were also analyzed by high-performance liquid chromatography. The antiproliferative effect on U937 cells was determined by MTT assay. The studied mycelia differ both in the enzymatic activities and protein content. The highest content in total phenol and the highest antioxidant activity for DPPH free radical scavenging and chelating activity on Fe<sup>2+</sup> were observed with the Gl-4 isolate of <i>G. lucidum</i>. The presence of quercetin, rutin, myricetin, and morin as major flavonoids with effective antioxidant activity was detected. The ethanolic extracts from mycelia of <i>G. lucidum</i> isolates possess a substantial antiproliferative activity against U937 cells in contrast to <i>G. resinaceum</i> in which the antiproliferative effects were insignificant. This study provides a comparison between <i>G. lucidum</i> and <i>G. resinaceum</i> mycelial strains, and shows that <i>G. resinaceum</i> could be utilized to obtain several bioactive compounds.